Abstract: Activation of the apelin/APJ receptor signaling system causes endothelium-dependent and nitric oxide (NO)-dependent relaxation in several peripheral arteries. The effects of apelin in cerebral arteries are unknown; however, apelin inhibits voltage-dependent increases in large-conductance, calcium-activated K channel (BK Ca ) currents in cerebral artery smooth muscle cells. Because NO-induced relaxation of cerebral arteries is mediated, in part, by activation of BK Ca channels, the goals of this study were to determine the net effect of apelin in cerebral arteries, as well as test the hypothesis that the actions of apelin in cerebral arteries are secondary to stimulation of APJ receptors. Immunoblot and quantitative reverse transcription polymerase chain reaction analyses detected APJ receptors in cerebral arteries of male Sprague-Dawley rats, and immunofluorescence studies using confocal microscopy confirmed APJ receptor localization in smooth muscle cells. In myograph studies, apelin itself had no direct vasomotor effect but inhibited relaxations to the NO-donor, diethylamine NONOate, and to the endothelium-dependent vasodilator, bradykinin. These effects of apelin were mimicked by the selective BK Ca -channel blocker, iberiotoxin, and suppressed by the APJ receptor antagonist, F13A. Apelin also inhibited relaxations evoked by the BK Ca -channel openers, NS1619 and BMS 191011, but had no effect on relaxation to levcromakalim, a selective K ATP -channel opener. Apelin had no effect on diethylamine NONOate-induced or bradykinin-induced increases in cyclic guanosine monophosphate levels. Patch clamp recordings demonstrated that apelin and iberiotoxin each suppressed the increase in BK Ca currents induced by DEA and NS1619 in freshly isolated cerebral artery smooth muscle cells. The results demonstrate that apelin inhibits NO-induced relaxation of cerebral arteries through a mechanism involving activation of APJ receptors and inhibition of BK Ca channels in cerebral arterial smooth muscle cells.
INTRODUCTION
Apelin is an endogenous peptide that is emerging as an important signaling molecule in several organ systems, including the cardiovascular system. 1 Apelin binds to a single G-protein-coupled receptor, termed APJ, which is widely expressed in peripheral organs and tissues as well as the central nervous system. 2, 3 With respect to the cardiovascular system, APJ receptors are found in heart, 4,5 blood vessels, 5, 6 and cardiovascular regulatory centers in the brain. 3, 7, 8 A growing body of evidence supports a role for the apelin/APJ receptor signaling system in the regulation of blood vessel diameter. Studies indicate that apelin is a powerful vasodilator with an efficacy that exceeds that of hydralazine or nitrates. 9, 10 This action, along with its inotropic effects on the heart, has led to the proposition that modulating the apelin/APJ system may offer a novel and rational therapeutic strategy for treating certain cardiovascular disorders, including myocardial ischemia, pulmonary arterial hypertension, and heart failure. 10, 11 A confounding factor, however, is that the effect of APJ receptor activation on vascular tone is dependent on the particular vascular bed being studied. Although APJ receptor stimulation leads to endothelium-dependent and NOdependent vasodilation in several blood vessels, 12, 13 it can also result in vascular smooth muscle contraction in others. 12, 14 These divergent vasomotor effects of apelin are consistent with the widely recognized heterogeneity that exists among blood vessels from different origins in terms of their reactivity to vasoactive agents. 15 Therefore, although systemic administration of apelin may have an overall beneficial hypotensive effect, it could also result in dangerous vasoconstriction in specific vascular beds.
Our knowledge of the vasomotor actions of apelin in specific blood vessels is rather limited at the present time. One important vascular bed that has not been rigorously investigated with respect to the apelin/APJ system is the cerebral vasculature; however, a potential vasoconstrictor role for apelin in the regulation of cerebral arterial tone is suggested by our recent finding that apelin inhibits largeconductance, calcium-activated K (BK Ca )-channel currents evoked by voltage-dependent increases in membrane potential in cerebral artery smooth muscle cells. 16 Thus, in cerebral arteries, the net effect of apelin on blood vessel diameter could be the result of the ability of APJ receptor activation on the endothelium to evoke NO-dependent relaxations on one hand versus the effect of APJ receptor activation on the smooth muscle to inhibit relaxation through interference with NO-induced increases in BK Ca currents. In this study, we directly assessed the question of the net effect of apelin in cerebral arteries, as well as the hypothesis that the actions of apelin in cerebral arteries are indeed secondary to stimulation of APJ receptors.
MATERIALS AND METHODS

Animals and Tissue Preparation
Experiments were performed on tissues isolated from 12-week-old male Sprague-Dawley rats (Envigo RMS, Indianapolis, IN). Rats were housed at 22 6 28C on a 12 hours-12 hours light-dark cycle and provided with food and water ad libitum. All animal protocols were approved by the North Dakota State University Institutional Animal Care and Use Committee. Brains were isolated from animals anesthetized with isoflurane and placed into ice-cold physiological salt solution (PSS) with the following composition (in mM): NaCl 119 mM, NaHCO 3 15 mM, KCl 4.6 mM, MgCl 2 1.2 mM, NaH 2 PO 4 1.2 mM, CaCl 2 1.5 mM, and glucose 5.5 mM. Middle cerebral arteries were dissected and cleaned of surrounding tissue.
Western Immunoblotting
After collection, cerebral arteries were immediately frozen in liquid nitrogen. Tissues were homogenized in lysis buffer and supplemented with a protease and phosphatase inhibitor cocktail (Santa Cruz Biotechnology Inc, Santa Cruz, CA) at 48C using an IKA Ultra-Turrax T8 homogenizer (IKA Works). Tissue homogenates were kept on ice for 10 minutes and then centrifuged at 10,000g for 10 minutes. Supernatant was collected and protein determination was performed using a Pierce bicinchoninic acid protein estimation kit (ThermoFisher Scientific, Waltham, MA). Aliquots of supernatant containing equal amounts of protein (40 mg) were separated on 7.5%-10% polyacrylamide gel by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and proteins were electroblotted onto a polyvinylidene difluoride membrane (Bio-Rad Laboratories, Hercules, CA). Blots were blocked with 5% nonfat dry milk in Tris-buffered saline (TBS, pH 7.4) and incubated overnight at 48C with a primary antibody specific for APJ receptors using a dilution of 1:200 (Santa Cruz Biotechnology Inc). Membranes were washed 3 times for 10 minutes using TBS-Tween 20 and incubated with a horseradish peroxidase-linked secondary antibody (Santa Cruz Biotechnology Inc). To ensure equal loading, the blots were analyzed for b-actin expression using an antiactin antibody (Santa Cruz Biotechnology Inc). Immunodetection was performed using an enhanced chemiluminescence light detection kit (ThermoFisher Scientific).
Quantitative Reverse Transcription Polymerase Chain Reaction
Freshly isolated arteries were immediately frozen in liquid nitrogen, and total RNA was isolated using an RNeasy Mini kit according to the manufacturer's protocol (Qiagen, Germantown, MD). The concentration and purity of RNA was determined using a spectrophotometer (Nanodrop Technologies, Wilmington, DE). cDNA was synthesized using 50 ng of RNA and an iScript cDNA synthesis kit (Bio-Rad Laboratories). A Sybr Green expression assay was used to determine expression of APJ receptors, with b-actin used as a housekeeping gene (Bio-Rad Laboratories). The following primers (synthesized by Invitrogen, Carlsbad, CA) were used: APJ receptor-forward: 5 0 -ACAAGACATGTGCCATTG-GA-3 0 ; reverse: 5 0 -TCTCCCAGAAGCCTCCTACA-3 0 and b-actin-forward: 5 0 -GTCGTACCACTGGCATTGTG-3 0 ; reverse: 5 0 -TCTCAGCTGTGGTGGTGAAG-3 0 . Real-time reverse transcription polymerase chain reaction reaction conditions were 958C for 10 minutes, followed by 40 cycles of 958C for 10 seconds, 608C for 20 seconds, and 728C for 30 seconds.
Immunofluorescence Microscopy
Freshly isolated cerebral arteries were fixed in 10% formalin solution, processed, and embedded in paraffin blocks. Paraffin blocks were sectioned at 7 mm and mounted onto ProbeOn Plus microscopic slides (ThermoFisher Scientific). Sections were fixed by heating at 608C for 30 minutes. Nonspecific antibody binding was blocked with normal serum (10% w/v; in TBS) for 1 hour at room temperature. Sections were incubated overnight at 48C in 1% serum containing a primary antibody against APJ receptors (Abcam, Cambridge, MA) and/or smooth muscle actin (Santa Cruz Biotechnology). For colocalization of APJ receptor with smooth muscle actin, double immunofluorescent staining was performed by incubating the tissue sections with more than one primary antibody at the same time. Detection of the primary antibodies against the APJ receptor and smooth muscle actin was accomplished using Texas red-conjugated (goat anti-rabbit IgG; Invitrogen, Carlsbad, CA) and Alexa Fluor-488 (goat anti-mouse IgG; Santa Cruz Biotechnology) secondary antibodies, respectively. Rat lung tissue was used as positive control for APJ receptor detection. 7 Negative controls were incubated overnight at 48C with 1% serum containing a primary isotype control antibody (nonimmune IgG; Abcam) from the same species (rabbit) as that of the APJ receptor antibody, followed by secondary antibodies. All dilutions and thorough washes between stages were performed using TBS-containing Triton X-100 (0.3% [v/v]) unless otherwise stated. Sections were drained by blotting with filter paper, and a drop of mounting medium containing an antifade reagent (Vector Laboratories, Burlingame, CA) was added to the slides. Images of the sections were obtained using an Olympus confocal laser scanning microscope (Olympus, Tokyo, Japan). The images were generated using Olympus FluoView FV300 (v. 4.3) confocal software.
Vascular Function Studies
Arterial rings (80-100 mm; 1.2 mm in length) were suspended in wire myographs (DMT, Aarhus, Denmark) for isometric tension recording. The myograph chambers were filled with PSS (5 mL), which was continuously aerated with 95% O 2 /5% CO 2 and maintained at 378C throughout the experiment. The vessel rings were stretched to an initial tension of 2 mN and then allowed to stabilize for 30-40 minutes with intermittent washings. Vessel reactivity was confirmed by evoking a response to KCl (60 mM). 17 In some vessels, the endothelium was removed by gently rubbing the intimal surface with a human hair. The presence or absence of endothelium was confirmed by measuring relaxation in response to the endothelium-dependent vasodilator, bradykinin (10 27 M). Responses to the vasodilators used in this study were obtained in arterial rings contracted with 5-hydroxytryptamine (5-HT) (10 27 M). Relaxation responses were obtained with the following: (1) diethylamine NONOate (DEA NONOate), an exogenous NO-donor 18 ; (2) bradykinin, which, in rat cerebral arteries, causes relaxation by releasing endothelium-derived (endogenous) NO 19, 20 ; (3) the BK Cachannel openers, NS1619 and BMS 191011 21, 22 ; and (4) the K ATP channel opener, levcromakalim. 23 Inhibitors were added to the myograph chamber 20 minutes before contraction with 5-HT, with the exception of apelin (10 27 M), which was added 5 minutes after the contraction had stabilized to minimize desensitization of APJ receptors. This concentration of apelin was selected because, in previous studies, it produced the greatest inhibitory effect on BK Ca -channel currents in rat cerebral smooth muscle cells. 16 Other inhibitors used included the following: (1) iberiotoxin, a selective BK Cachannel blocker 24 ; (2) F13A, a selective APJ receptor antagonist 25 ; and (3) the nitric oxide synthase inhibitor, nitro-L-arginine. After addition to the myograph chamber, the inhibitors remained in contact with the tissues for the remainder of the experiment. Experiments with inhibitors were conducted in parallel with untreated control rings taken from the same animal.
Cerebral Artery Smooth Muscle Cell Isolation
Enzymatic isolation of single vascular smooth muscle cells was performed as described previously, with brief modification. 26 Arteries were placed in cell isolation solution of the following composition (in mM): 60 NaCl, 80 Naglutamate, 5 KCl, 2 MgCl 2 , 10 glucose, and 10 HEPES (pH 7.2). Arterial segments were initially incubated in 1.2-mg/mL papain (Worthington, Lakewood, NJ) and 2.0-mg/mL dithioerythritol (Sigma Aldrich, St. Louis, MO) for 17 minutes at 378C and then in 0.8 mg/mL type II collagenase (Worthington) for 12 minutes at 378C. The digested segments were washed 3 times in ice-cold cell isolation solution and incubated on ice for 30 minutes. After this incubation period, vessels were triturated to liberate smooth muscle cells and stored in ice-cold cell isolation solution for use. Smooth muscle cells were studied within 6 hours after isolation.
Electrophysiological Recording
Isolated smooth muscle cells were placed into a recording chamber (Warner Instruments, Hamden, CT) and allowed to adhere for 20 minutes at room temperature. Whole-cell currents were recorded using an AxoPatch 200B amplifier equipped with an Axon CV 203BU headstage (Molecular Devices, Sunnywale, CA). Current data were collected and analyzed with pCLAMP 10.0 software (Molecular Devices). The patch electrodes (3-4 MV) were fabricated from 1.5-mm borosilicate glass capillaries. Smooth muscle cells were superfused at a rate of 2.0 mL/min with a solution containing (in mM) 145 NaCl, 5.4 KCl, 1.8 CaCl 2 , 1 MgCl 2 , 5 HEPES, 10 glucose; pH 7.4 (NaOH). Patch pipettes were filled with internal pipette solution containing (in mM) 145 KCl, 5 NaCl, 0.37 CaCl 2 , 2 MgCl 2 , 10 HEPES, 1 EGTA, 7.5 Glucose; pH 7.2 (KOH). All drugs were diluted in fresh bath solution and perfused into the experimental chamber. Voltage-activated currents were filtered at 2 kHz and digitized at 10 kHz, and capacitive and leakage currents were subtracted digitally. Series resistance and total cell capacitance were calculated from uncompensated capacitive transients in response to 10-ms hyperpolarizing step pulses (5 mV), or obtained by adjusting series resistance and whole-cell capacitance using the Axopatch 200B amplifier control system. Standard recording conditions for BK Ca currents were achieved by stepping in 10-mV increments from a holding potential of 260 to +80 mV. BK Ca currents were expressed as current density (current divided by its capacitance).
Cyclic GMP Estimation
A competitive ELISA method was used to measure cyclic guanosine monophosphate (GMP) levels in cerebral arteries. Arterial segments were equilibrated in PSS for at least 20 minutes at 378C. After the equilibration period, arterial segments were treated with bradykinin (10 27 M, 5 minutes) or DEA NONOate (DEA; 10 26 M, 5 minutes). In some experiments, arterial segments were pretreated with apelin (10 27 M) for 5 minutes, before being exposed to bradykinin or DEA NONOate. After drug treatments, segments were immediately frozen in liquid nitrogen and homogenized with an IKA Ultra, Turrax-T8 homogenizer (IKA Works Inc, Wilmington, NC) at 48C in 0.1-M hydrochloric acid. Tissue homogenates were centrifuged for 10 minutes at $600g. Cyclic GMP and total protein content were determined in the supernatant as described in the direct cyclic GMP enzyme immunoassay kit (Assay Design, Ann Arbor, MI) and Pierce bicinchoninic acid protein assay kit (ThermoFisher Scientific), respectively. Cyclic GMP levels were expressed as picomoles per microgram of protein.
Data Analysis
Relaxation responses are expressed as a percent of the initial tension induced by 5-HT (10 27 M). EC 50 values (drug concentration that produced 50% of its own maximal response) were determined, converted to their negative logarithms, and expressed as -log molar EC 50 (pD 2 ). Quantitative reverse transcription polymerase chain reaction data were analyzed to quantify relative gene expression by DCt relative to b-actin. All results are expressed as mean 6 SEM, and n refers to the number of animals from which blood vessels were taken. Values were compared by Student's t-test or 1-way analysis of variance using Tukey's test as post hoc analysis for paired or unpaired observations, as appropriate, to determine significance between groups. Values were considered significantly different when P , 0.05. and NS1619 (Sigma Chemical, St. Louis, MO); BMS 191011, and iberiotoxin, (Tocris, Ellisville, MO); apelin-13, and F13A (H-Gln-Arg-Pro-Arg-Leu-Ser-His-Lys-Gly-ProMet-Pro-Ala-OH trifluoroacetate salt) (Bachem, Torrance, CA). Drug solutions were prepared fresh daily, kept on ice, and protected from light until used. All drugs were dissolved in double-distilled water with the exception of BMS 191011 and NS1619, which were dissolved initially in dimethyl sulfoxide before further dilution in double-distilled water. Drugs were added to the myograph chambers in volumes not greater than 0.02 mL. Drug concentrations are reported as final molar concentrations in the myograph chamber.
RESULTS
APJ Receptor Expression in Cerebral Arteries
Western immunoblot analysis demonstrated expression of APJ receptor protein in rat cerebral arteries. A strong immunoreactive band at 42 kDa corresponding to APJ receptors was detected in immunoblots of cerebral artery homogenates and in rat lung used as a positive control ( Figure  1A ). 7 Quantitative reverse transcription polymerase chain reaction analysis confirmed the expression of mRNA transcripts in rat cerebral arteries ( Figure 1B ). In immunofluorescence studies, APJ receptor protein was immunodetected in rat cerebral arteries and localized to the smooth muscle cell layer and endothelium ( Figure 1C.1 ). Smooth muscle cell actin was detected in the smooth muscle cell layer ( Figure  1C. 2), and APJ receptors were co-localized with smooth muscle cell actin in the smooth muscle cell layer of the cerebral artery ( Figure 1C.3) . Incubation of arteries with an isotype negative control antibody, followed by the secondary antibody, demonstrated a lack of nonspecific binding of secondary antibody in the absence of primary APJ receptor antibody ( Figure 1C.5) . Similar results were obtained in rat lung, which demonstrated immunostaining for APJ receptors on bronchial epithelium ( Figure 1C.6 ).
Vascular Relaxation Studies
In cerebral arteries contracted with 5-HT (10 27 M), addition of increasing concentrations of apelin (10 28 2 3 · 10 26 M) to the preparations had no effect on vasomotor tone in rings with or without endothelium (Figure 2) . Likewise, these concentrations of apelin had no effect on resting tone in quiescent cerebral arterial rings (data not shown).
DEA NONOate (10 29 2 10 25 M) caused concentration-dependent relaxation of endothelium-denuded cerebral arteries contracted with 5-HT (10 27 M) (Figure 3) . The concentration-response curve to DEA NONOate was inhibited in the presence of apelin (10 27 M) ( Figure 3A) ; the pD 2 values for DEA NONOate were 6.92 6 0.20 versus 6.13 6 0.08, in the absence and presence of apelin, respectively (P , 0.05). Iberiotoxin (10 27 M) had an inhibitory effect on the response to DEA NONOate that was similar to that observed with apelin ( Figure 3B ). The corresponding pD 2 values for DEA NONOate were 6.98 6 0.21 versus 6.14 6 0.13, without and with iberiotoxin, respectively (P , 0.05). Treatment with a combination of apelin (10 27 M) plus iberiotoxin (10 27 M) had no greater inhibitory effect on DEA NONOate-induced relaxation of isolated cerebral arteries (pD 2 = 6.19 6 0.07; n = 6) than either apelin or iberiotoxin alone. F13A (10 27 M), which had no effect of its own on the response to DEA NONOate, abolished the inhibitory effect of apelin on DEA NONOate-induced relaxation ( Figure 3C ).
Bradykinin-induced relaxation of endothelium-intact cerebral arteries was also inhibited in the presence of apelin (10 27 M), as evidenced by a significant difference in pD 2 values for bradykinin (7.76 6 0.20 vs. 7.03 6 0.12, in the absence and presence of apelin, respectively; P , 0.05) and a reduction in the maximal relaxation response ( Figure 4A ). Iberiotoxin (10 27 M) had an inhibitory effect on the bradykinin concentration-response curve that was similar to that observed with apelin ( Figure 4B) ; the pD 2 values for bradykinin were 8.02 6 0.21 versus 7.19 6 0.22 in the absence and presence of iberiotoxin, respectively (P , 0.05). The effect of combined treatment with apelin (10 27 M) plus iberiotoxin (10 27 M) on bradykinin-induced relaxation of isolated cerebral arteries was similar to that observed with either inhibitor alone (pD 2 = 7.15 6 0.17; n = 6). In the presence of nitro-Larginine (3 · 10 25 M), the response to bradykinin was nearly abolished and neither apelin nor iberiotoxin had any effect on bradykinin-induced relaxations (see Figure 1 , Supplemental Digital Content 1, http://links.lww.com/JCVP/A288). As observed in the experiments with DEA NONOate, F13A (10 27 M) had no effect on the response to bradykinin but abolished the inhibitory effect of apelin on bradykinininduced relaxation ( Figure 4C) .
Apelin inhibited the responses to equieffective concentrations of NS1619 and BMS 191011 ( Figure 5A and 5B) but had no effect on levcromakalim-induced relaxation of similar magnitude in endothelium-denuded cerebral arteries ( Figure 5C ).
Electrophysiology Studies
DEA NONOate (10 25 M) caused a significant increase in whole-cell BK Ca -channel current measured in freshly isolated cerebral arterial smooth muscle cells ( Figure 6 ). The DEA NONOate-induced increase in BK Ca -channel current was nearly abolished by apelin (10 27 M) ( Figure 6A-E) ; however, in the presence of F13A (10 27 M), apelin (10 27 M) had no effect on the DEA NONOate-induced increase in BK Ca -channel current [peak current density (+80 mV) = 79.3 6 7.2 with DEA NONOate alone vs. 77.7 6 5.5 pA/pF with DEA NONOate in the presence of apelin plus F13A; P . 0.05; n = 6]. As was observed in the vascular relaxation studies, the inhibitory effect of apelin on the response to DEA NONOate was mimicked by iberiotoxin (10 27 M) ( Figure 6F ). Likewise, apelin (10 27 M) also suppressed the NS1619-induced increase in BK Ca -channel current in isolated cerebral arterial smooth muscle cells ( Figure 6G ). 
Cyclic GMP Measurements
DEA NONOate caused a significant increase in intracellular cyclic GMP levels in cerebral arteries. The basal level of cyclic GMP was 0.05 6 0.01 pmol/mg protein and increased to 0.28 6 0.06 pmol/mg in the presence of DEA NONOate (10 26 M) (P , 0.05; n = 6). Cyclic GMP levels in the presence of DEA NONOate plus apelin (10 27 M) were 0.26 6 0.03 pmol/mg and did not differ significantly from those observed with DEA NONOate alone (P . 0.05; n = 6). Bradykinin also caused a significant increase in intracellular cyclic GMP levels in cerebral arteries. The basal level of cyclic GMP was 0.06 6 0.02 pmol/mg protein and increased to 0.28 6 0.05 pmol/mg in the presence of bradykinin (10 26 M) (P , 0.05; n = 5). In the presence of apelin (10 27 M), the bradykinin-induced increase in cyclic GMP levels was 0.23 6 0.04 pmol/mg and did not differ significantly from that observed with bradykinin alone (P . 0.05; n = 5).
DISCUSSION
The major finding of this study is that receptors for apelin (ie, APJ receptors) are expressed in cerebral arteries and that activation of these receptors on vascular smooth muscle cells inhibits NO-induced relaxation. This conclusion, which identifies a previously unrecognized, novel action of apelin in blood vessels, is based on the findings that (1) APJ receptor mRNA and protein are expressed in cerebral arteries; (2) APJ receptor protein colocalizes with smooth muscle cell actin in the arterial wall; (3) apelin inhibits relaxation of cerebral arteries in response to endothelium-derived NO, as well as an NO-donor; and (4) the inhibitory effects of apelin on NO-induced relaxation are abolished by an APJ receptor antagonist. Moreover, the findings indicate that apelin inhibits relaxation of cerebral arteries to NO by attenuating NOinduced increases in BK Ca current in arterial smooth muscle cells. When taken together with the observation that apelin failed to cause relaxation in cerebral arteries, these actions of apelin could be expected to result in a net increase in cerebral vasomotor tone.
The results of this study demonstrate for the first time that APJ receptor gene transcripts and proteins are expressed in cerebral arteries. Moreover, immunofluorescence colocalization studies indicate that APJ receptors are present on both vascular smooth muscle and endothelial cells in the cerebral arterial wall, suggesting the possibility that APJ receptors may be involved in the local regulation of cerebral artery vasomotor tone. Evidence for a functional role for APJ receptors in regulating vascular tone is supported by both in vivo and in vitro studies. Intravenous administration of exogenous apelin has been reported to cause both an increase and a decrease in mean arterial blood pressure, 9, 27, 28 and, in humans, apelin increases forearm and coronary blood flow. 29, 30 In isolated arterial rings, apelin causes endothelium-dependent relaxations under normal conditions, 12,13 whereas vascular smooth muscle contraction is observed in blood vessels in which the endothelium has been removed or damaged. 12, 14 Nonetheless, apelin failed to cause either contraction or relaxation of isolated cerebral arteries, regardless of the status of the endothelium and despite the presence of APJ receptors on vascular smooth muscle and endothelial cells in these arteries. These results demonstrate that apelin itself does not directly alter vasomotor tone in cerebral arteries, in contrast to its actions reported in other arteries studied thus far.
A key finding of this study is that despite having no measurable direct effect on cerebrovascular tone, apelin inhibited relaxations in response to bradykinin (endogenous NO) 19, 20 and to DEA NONOate (exogenous NO). 18 Because APJ receptors are expressed on cerebral artery endothelial cells, one potential site of action for apelin, at least with regard to endogenously produced NO, could be inhibition of endothelial nitric oxide synthase (eNOS); however, the only-published reports regarding the regulation of eNOS by apelin indicate that the peptide increases, rather than inhibits, eNOS activity. 31, 32 Although an effect of apelin on eNOS in cerebral arteries cannot be ruled out by this study, the observation that apelin also inhibits NO-induced relaxation in response to DEA NONOate, which acts independently of the endothelium and suggests a site of action other than or in addition to eNOS. These results, together with data from the molecular studies indicating that cerebral arterial smooth muscle cells express APJ receptors, are consistent with an inhibitory effect of apelin at the level of the vascular smooth muscle, which is the primary site of action for the relaxing effect of NO. 33, 34 Moreover, that the inhibitory effects of apelin on both the functional and electrophysiological responses to NO were blocked by pharmacologic inhibition with F13A, an APJ receptor antagonist, 25 strongly suggests that activation of APJ receptors on smooth muscle cells mediates this effect of apelin in cerebral arteries.
The finding that apelin inhibits NO-induced relaxation in cerebral arteries stands in contrast to its putative beneficial vasodilator effects reported in several peripheral arteries. Given the considerable heterogeneity known to exist among blood vessels from different origins in terms of their reactivity to vasoactive agents, it is not necessarily surprising that cerebral arteries may differ from peripheral arteries in their response to apelin. In the rat, for example, the pineal hormone, melatonin, is a potent vasoconstrictor in isolated cerebral arteries 35 but causes relaxation of isolated aorta and caudal artery. 36, 37 The reasons for the divergent responses to apelin among different blood vessels are not yet readily apparent, but possible explanations could include (1) differences in the subtype of APJ receptor expressed in smooth muscle of cerebral versus peripheral arteries; however, it should be noted that there are no reports in the literature of multiple APJ receptor subtypes; (2) differences in the intracellular signaling pathways coupled to APJ receptor activation in cerebral versus peripheral arteries; and (3) differences in the role of BK Ca channels in NO-induced relaxation among blood vessels.
The apelin/APJ receptor-signaling axis is generally considered to play a protective role in the cardiovascular system, with suggested benefits in disorders such as ischemiareperfusion injury, heart failure, and pulmonary hypertension. 10, 11, 38 Although apelin may have protective vasodilator effects in certain arteries (eg, pulmonary vascular bed), it is evident from this study that, in cerebral arteries, the net effect of APJ receptor activation could adversely affect cerebrovascular function. This may present an important caveat when exploring the cardiovascular efficacy of systemically administered APJ receptor agonists. Indeed, apelin-like analogs are now in preclinical development as potential therapeutic agents for myocardial infarction and ischemia-reperfusion injury, 38 and apelin itself is currently being administered to patients in clinical trials because of its putative beneficial effects on cardiac function and the pulmonary circulation. 30, 39 The cerebrovascular consequences of such drugs may be particularly significant in certain patients, inasmuch as a singlenucleotide polymorphism in the gene encoding the human APJ receptor, which results in increased apelin/APJ receptor signaling, has recently been identified and is associated with an increased risk of brain infarction. 40 Given the potential of sex hormones in regulating mechanisms of vasodilatation, it will also be important to determine whether the effects of apelin on NO-induced relaxation reported in male arteries in this study are also observed in cerebral arteries from females. Such information may have significant implications for drug development with regard to possible adverse effects in specific end organs, such as brain. Because impaired vasodilation is a hallmark characteristic of the vascular dysfunction that occurs in many forms of cardiovascular disease, 34 it is interesting to note that endogenous apelin levels are elevated in conditions such as obesity and diabetes, [41] [42] [43] which are major risk factors for stroke and other cerebrovascular disorders. 44 The molecular mechanism by which APJ receptor activation causes impaired relaxation to NO is likely due to inhibition of NO-induced increases in BK Ca -channel current in cerebral smooth muscle cells. In cerebral arteries of the rat, NO-induced relaxation is mediated in part by increased BK Cachannel activity and in part by increased formation of intracellular cyclic GMP resulting from activation of soluble guanylyl cyclase. [45] [46] [47] Because apelin had no effect on the increase in cyclic GMP levels evoked by either bradykinin or DEA NONOate, it is unlikely that inhibition of guanylyl cyclase underlies the ability of apelin to reduce NO-induced relaxation in cerebral arteries. However, a role for BK Ca channels in the effect of apelin is supported by several pieces of evidence, including (1) apelin inhibited the increases in BK Ca current induced by DEA NONOate and NS1619 in cerebral arterial smooth muscle cells; (2) the effects of apelin on both the functional and electrophysiological responses to NO were mimicked by iberiotoxin, a potent, and selective BK Ca -channel blocker 24 ; (3) combined treatment with apelin plus iberiotoxin had no greater effect on NO-induced relaxation than either inhibitor alone, consistent with a shared mechanism of action for apelin and iberiotoxin; and (4) apelin inhibited relaxation of endothelium-denuded cerebral arteries in response to the chemically distinct BK Ca -channel activators, BMS 191011 and NS1619, 21, 22 without affecting the response to the K ATP -channel opener, levcromakalim. 23 Taken together, the data indicate that the effect of apelin on BK Ca channels is sufficient to meaningfully impair cerebral arterial relaxation evoked by NO and other BK Ca -channelactivating molecules. Although the primary focus in this study was to identify the mechanism(s) by which apelin inhibits NO-induced relaxation of cerebral arteries, it will be important to identify the downstream intracellular signaling pathway(s) linking APJ receptor activation to inhibition of NO-induced increases in BK Ca current in cerebral arterial smooth muscle. In this regard, a possible role for the PI3-kinase/Akt pathway is suggested by our recent findings that apelin increases Akt phosphorylation in cerebral arterial smooth muscle cells, and inhibition of PI3-kinase markedly attenuates the inhibitory effect of apelin on voltage-dependent increases in BK Ca -channel current. 16 In summary, apelin activates APJ receptors in cerebral arterial smooth muscle cells, resulting in inhibition of BK Ca currents and reduced relaxation to endogenous and exogenous NO in cerebral arteries from male rats. Whether the ability of apelin to regulate vasomotor tone by inhibiting NO-induced relaxation is unique to the cerebral circulation is not yet clear, but given the pivotal role of NO in controlling vascular function, it will be important to determine whether this novel effect of apelin is observed in other blood vessels. The potential for adverse effects on the cerebral circulation to occur with the use of APJ receptor-activating drugs merits further consideration in future studies.
